Celgene Corporation (CELG) Shares Bought by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC grew its stake in Celgene Corporation (NASDAQ:CELG) by 0.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,054 shares of the biopharmaceutical company’s stock after buying an additional 18 shares during the period. Flagship Harbor Advisors LLC’s holdings in Celgene Corporation were worth $253,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. State Street Corp boosted its holdings in shares of Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Celgene Corporation by 4.9% in the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after buying an additional 472,067 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Celgene Corporation by 4.4% in the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after buying an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. boosted its holdings in shares of Celgene Corporation by 15.7% in the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Celgene Corporation by 4.3% in the 1st quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock valued at $446,406,000 after buying an additional 147,263 shares in the last quarter. Institutional investors and hedge funds own 79.43% of the company’s stock.

Celgene Corporation (CELG) traded up 0.17% during trading on Tuesday, reaching $141.16. 840,026 shares of the company’s stock traded hands. The stock has a market capitalization of $110.44 billion, a P/E ratio of 43.72 and a beta of 1.89. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $142.64. The company has a 50-day moving average of $134.21 and a 200 day moving average of $126.84.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.44 EPS. On average, equities research analysts expect that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

In other Celgene Corporation news, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the sale, the insider now owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 263,011 shares of company stock worth $35,078,473. Corporate insiders own 0.95% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Bought by Flagship Harbor Advisors LLC” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/09/12/celgene-corporation-celg-shares-bought-by-flagship-harbor-advisors-llc.html.

Several research analysts have recently issued reports on CELG shares. Goldman Sachs Group, Inc. (The) restated a “sell” rating and issued a $98.00 target price (up previously from $93.00) on shares of Celgene Corporation in a report on Wednesday, May 17th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $134.80 target price for the company in a report on Wednesday, May 17th. Robert W. Baird restated an “outperform” rating and issued a $162.00 target price on shares of Celgene Corporation in a report on Monday, May 22nd. BMO Capital Markets restated an “outperform” rating and issued a $152.00 target price on shares of Celgene Corporation in a report on Tuesday, May 23rd. Finally, Credit Suisse Group set a $148.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and twenty-two have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $147.31.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply